Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|February 24, 2026
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer"Dorine A de Bont, Trudy Straetemans, Zsolt Sebestyén, et al.Expert Opinion on Biological Therapy|February 12, 2010
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studiesMiriam Coccoris, Trudy Straetemans, Coen Govers, et al.Oncoimmunology|April 9, 2016
The next step toward GMP-grade production of engineered immune cellsGuido J J Kierkels, Trudy Straetemans, Moniek A de Witte, et al.Frontiers in Immunology|November 23, 2013
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuAndre Kunert, Trudy Straetemans, Coen Govers, et al.Cancer Immunology, Immunotherapy : CII|May 21, 2015
Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challengeMoniek A de Witte, Guido J J Kierkels, Trudy Straetemans, et al.Nature Reviews. Cancer|June 2, 2025
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapyDennis X Beringer, Trudy Straetemans, Susana Minguet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2015
Untouched GMP-Ready Purified Engineered Immune Cells to Treat CancerTrudy Straetemans, Cordula Gründer, Sabine Heijhuurs, et al.Developmental and Comparative Immunology|July 13, 2010
Successive immunoglobulin and cytokine expression in the small intestine of juvenile chickenAart Lammers, Willemien H Wieland, Leo Kruijt, et al.Viruses|January 22, 2022
The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and ChallengesAnke Janssen, Eline van Diest, Anna Vyborova, et al.Journal for Immunotherapy of Cancer|March 16, 2019
Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cellsInez Johanna, Trudy Straetemans, Sabine Heijhuurs, et al.Pageof 3